Home » Biotechnology » Recombinant Vaccines Market

Recombinant Vaccines Market By Disease (Infectious Diseases, Cancer) – Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Name: Recombinant Vaccines Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2017-11-23
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: Recombinant Vaccines Market

Summary
Table Of Content
Request Sample

Market Insights

Vaccines play a significant role in the prevention and control of different forms of infectious diseases. In the previous years, killed or attenuated vaccines were used, gradually transitioning to a recombinant subunit approach in the last two decades. The use of recombinant technologies in the production of subunit vaccines simplifies, secures, and reduces costs. A recombinant vaccine is manufactured using recombinant DNA technology, and it offers the prime advantage that there is a complete absence of pathogens during the production and purification procedures, thus making the production procedure safer.

The research study titled “Recombinant Vaccines Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” covers in-depth information related to the recombinant vaccines market. The research study provides a comprehensive analysis based on different market segments, such as disease type and geography. Infectious diseases and cancer are covered in the disease type segment analysis. The infectious diseases segment is further classified as hepatitis B infection, herpes zoster infection, influenza infection, and other infectious diseases.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

The global recombinant vaccines market is made up of North America (including the United States and Canada), Europe (including the United Kingdom and Germany), Asia Pacific (including Japan and China), Latin America (including Mexico and Brazil), and the Middle East and Africa (GCC). The market size and forecast for these regions, along with their cross-sectional segmentation, are provided in this report for the considered period. The regional markets are further studied in terms of major country-specific markets.

Quantitative data and qualitative information are included in this report for further understanding of the current market situation and possible future scenarios. Information such as market dynamics (drivers, opportunities, and challenges) gives a detailed idea of the current developments in the global recombinant vaccine market. The report also includes competitive profiling of prominent players, attractive investment propositions, and market positions of key leaders involved in the global recombinant vaccine market to assist with strategic decisions about the recombinant vaccine market.

Based on disease type, the global recombinant vaccine market is segmented as follows:

Infectious diseases

Hepatitis B infection
herpes zoster infection
Influenza Infection
Other Infectious Diseases
Cancer

According to the World Health Organization (WHO), the vaccine market is essentially dependent on the governments of industrialized and developing countries, the private sector, and various regulatory and advisory bodies. Recombinant DNA vaccines are third-generation vaccines produced by using recombinant DNA technology or genetic engineering to prevent different diseases. These vaccines are more advanced than conventional vaccines in preventing diseases such as hepatitis, herpes, papillomavirus infection, influenza, etc. The recombinant vaccines market will grow significantly during the forecast period as it involves a novel method to elicit humoral as well as cellular immune responses, reduced risk of pathogenicity, and an easier approach for large-scale production.

In 1986, the first hepatitis B recombinant vaccine was approved in the United States. Currently, hepatitis B infection is a major revenue-generating segment, as the hepatitis B vaccine is included in the World Health Organization’s list of essential medicines. Moreover, the Centers for Disease Control and Prevention (CDC), the American Academy of Pediatrics (AAP), and the American College of Obstetricians and Gynecologists (ACOG) also strongly recommend hepatitis B vaccination. Currently, hepatitis B recombinant vaccine revenue is largely generated by Engerix-B, Recombivax-HB, Pediarix, Comvax, Twinrix, etc. GlaxoSmithKline and Merck are the key players in the hepatitis B vaccine market. Promising pipeline vaccines such as VPM1002 (BCG), EBOV-GP (Ebola), Shingrix (Herpes Zoster), GSK-2189242A (pneumococcal infections), ID-93 (tuberculosis), PROSTVAC-VF (prostate cancer), etc. are expected to further assist the market’s growth during the forecast period of 2017–2025.

The recombinant vaccines market is divided into three segments for the purposes of this study:

North America

- United States
- Canada
Europe
- United Kingdom
- Germany
- Rest of Europe
Asia Pacific
- Japan
- China
- Rest of Europe
Latin America
- Brazil
- Mexico
- rest of Latin America
Middle East and Africa
- GCC
- Rest of the Middle East and Africa

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Recombinant vaccines are a more advanced, efficient, and safe technique produced by using recombinant DNA technology or genetic engineering. According to the World Health Organization (WHO), demand for vaccines mainly depends on the governments of countries, the pooling of procurement agencies, the proliferation of private players, and the presence and involvement of various regulatory and regulatory bodies overseeing vaccine safety and quality. The WHO also estimated that high-income countries such as the United States, the United Kingdom, France, etc., contribute over 80% of vaccine revenue due to the faster adoption of newer vaccines and higher costs. According to research, North America held the largest market share in 2016 due to higher recombinant vaccine costs, increased healthcare awareness, the strong recommendation of immunization programs, faster implementation of newer vaccines, and widespread availability of FDA-approved recombinant vaccines for various indications. Favorable R&D activities and the strong presence of pipeline vaccines such as VPM1002, EBOV-GP, Shingrix, GSK-2189242A, ID-93, PROSTVAC-VF, etc., would further assist the recombinant vaccine market’s growth in North America. It is also estimated that Asia Pacific will show the fastest market growth during the forecast period due to increasing healthcare awareness and rising government initiatives in the immunization program. According to the WHO, middle- and low-income countries generate approximately 18% of the value of total global vaccine sales, constituting around 80% of the annual volume sold. The WHO estimated that vaccine demand from the private sector is relatively small, i.e., about 5–10% of the total vaccine sales in developing countries.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Recombinant Vaccines Market Snapshot
2.2 Global Recombinant Vaccines Market, by Disease (US$ Bn)
2.3 Global Recombinant Vaccines Market Share, by Geography, 2016 (Value %)

Chapter 3 Recombinant Vaccines Market Analysis
3.1 Global Recombinant Vaccines Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Attractive Investment Proposition, 2016
3.4 Competitive Landscape of Key Players in Recombinant Vaccines Market
3.5 Top 3 Countries

Chapter 4 Pipeline Analysis of Recombinant Vaccines
4.1 Overview
4.2 Projected Sales of Phase III Recombinant Vaccines Estimated Till 2025 (US$ Bn)
4.2 Tabular Representation of Phase II and I Recombinant Vaccines

Chapter 5 Global Recombinant Vaccines Market, by Disease, 2015-2025 (US$ Bn)
5.1 Overview
5.2 Attractive Investment Proposition: Global Recombinant Vaccines Market, by Disease, 2016
5.3 Infectious Diseases
5.3.1 Hepatitis B Infection
5.3.2 Herpes Zoster Infection
5.3.3 Influenza Infection
5.3.4 Other Infectious Diseases
5.4 Cancer

Chapter 6 Global Recombinant Vaccines Market, by Geography, 2015-2025 (US$ Bn)
6.1 Preface
6.2 North America
6.2.1 North America Recombinant Vaccines Market, by Disease, 2015- 2025 (US$ Bn)
6.2.2 North America Recombinant Vaccines Market, by Country, 2015- 2025 (US$ Bn)
6.2.2.1 United States
6.2.2.2 Canada
6.3 Europe
6.3.1 Europe Recombinant Vaccines Market, by Disease, 2015- 2025 (US$ Bn)
6.3.2 Europe Recombinant Vaccines Market, by Country, 2015- 2025 (US$ Bn)
6.3.2.1 U.K.
6.3.2.2 Germany
6.3.2.3 Rest of Europe
6.4 Asia Pacific
6.4.1 Asia Pacific Recombinant Vaccines Market, by Disease, 2015- 2025 (US$ Bn)
6.4.2 Asia Pacific Recombinant Vaccines Market, by Country, 2015- 2025 (US$ Bn)
6.4.2.1 China
6.4.2.2 Japan
6.4.2.3 Rest of Asia Pacific
6.5 Latin America
6.5.1 Latin America Recombinant Vaccines Market, by Disease, 2015- 2025 (US$ Bn)
6.5.2 Latin America Recombinant Vaccines Market, by Country, 2015- 2025 (US$ Bn)
6.5.2.1 Brazil
6.5.2.2 Mexico
6.5.2.3 Rest of Latin America
6.6 Middle East and Africa
6.6.1 Middle East and Africa Recombinant Vaccines Market, by Disease, 2015- 2025 (US$ Bn)
6.6.2 Middle East and Africa Recombinant Vaccines Market, by Country, 2015- 2025 (US$)
6.6.2.1 GCC
6.6.2.3 Rest of Middle East and Africa

Chapter 7 Company Profiles
7.1 Bharat Biotech
7.2 GlaxoSmithKline Plc.
7.3 MedImmune, LLC
7.4 Merck & Co. Inc.
7.5 Novartis AG
7.6 Pfizer Inc.
7.7 Protein Science Corporation
7.8 Sanofi Aventis
7.9 Serum Institute of India

List of Figures

FIG. 1 Recombinant Vaccines Market: Research Methodology
FIG. 2 Global Recombinant Vaccines Market, by Disease, 2016 (US$ Bn)
FIG. 3 Global Recombinant Vaccines Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Recombinant Vaccines Market, by Geography, 2016
FIG. 5 Attractive Investment Proposition: Global Recombinant Vaccines Market, by Disease, 2016
FIG. 6 Global Hepatitis B Infection Recombinant Vaccines Market, 2015 – 2025 (US$ Bn)
FIG. 7 Global Herpes Zoster Infection Recombinant Vaccines Market, 2015 – 2025 (US$ Bn)
FIG. 8 Global Influenza Infection Recombinant Vaccines Market, 2015 – 2025 (US$ Bn)
FIG. 9 Global Other Infectious Diseases Recombinant Vaccines Market, 2015 – 2025 (US$ Bn)
FIG. 10 Global Cancer Recombinant Vaccines Market, 2015 – 2025 (US$ Bn)

List of Tables

TABLE 1 Market Positioning of Key Players in Global Recombinant Vaccines Market
TABLE 2 Top 3 Countries in Global Recombinant Vaccines Market
TABLE 3 Global Recombinant Vaccines Market, by Disease, 2015 – 2025 (US$ Bn)
TABLE 4 Global Infectious Disease Recombinant Vaccines Market, by Type, 2015 – 2025 (US$ Bn)
TABLE 5 Global Recombinant Vaccines Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 6 North America Recombinant Vaccines Market, by Disease, 2015-2025 (US$ Bn)
TABLE 7 North America Recombinant Vaccines Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 8 Europe Recombinant Vaccines Market, by Disease, 2015-2025 (US$ Bn)
TABLE 9 Europe Recombinant Vaccines Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 10 Asia Pacific Recombinant Vaccines Market, by Disease, 2015-2025 (US$ Bn)
TABLE 11 Asia Pacific Recombinant Vaccines Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 12 Latin America Recombinant Vaccines Market, by Disease, 2015-2025 (US$ Bn)
TABLE 13 Latin America Recombinant Vaccines Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 14 Middle East and Africa Recombinant Vaccines Market, by Disease, 2015-2025 (US$ Bn)
TABLE 15 Middle East and Africa Recombinant Vaccines Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 16 Bharat Biotech: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 17 GlaxoSmithKline Plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 18 MedImmune, LLC: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 19 Merck & Co. Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 20 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 21 Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 22 Protein Science Corporation: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 23 Sanofi Aventis: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 24 Serum Institute of India: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

Request Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Frequently Asked Questions

What is the size of Recombinant Vaccines Market?

The market for Recombinant Vaccines is expected to reach US$ XX Mn in 2025.

What is the Recombinant Vaccines Market CAGR?

The Recombinant Vaccines market is expected to see significant CAGR growth over the coming years,at 6.4%.

What is the Forecast period considered for Recombinant Vaccines Market?

The report is forecasted from 2017-2025.

What is the base year considered for Recombinant Vaccines Market?

The base year of this report is 2016.

Who are the major players in this Market?

Bharat Biotech,GlaxoSmithKline Plc., MedImmune, LLC, Merck & Co. Inc.Novartis AG are some of the major players in the global market.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Antibody and Recombinant Protein CDMO Market

The Antibody and Recombinant Protein CDMO Market is projected to grow from USD 18,141.86 million in 2024 to USD 40,589 million by 2032, registering a compound annual growth rate (CAGR) of 10.59%.

Prokaryotic Recombinant Protein Market

The Prokaryotic Recombinant Protein Market is projected to grow from USD 2725.2 million in 2024 to an estimated USD 4278.42 million by 2032, with a compound annual growth rate (CAGR) of 5.8% from 2024 to 2032.

Recombinant DNA Technology Market

The global Recombinant DNA Technology Market is set to witness substantial growth, with its market size projected to expand from USD 172,915 million in 2024 to USD 340,769 million by 2032, reflecting a robust compound annual growth rate (CAGR) of 8.85% during the forecast period.

Recombinant Protein Market

The Recombinant Protein Market is projected to experience substantial growth, with its value expected to surge from USD 1,897.70 million in 2023 to USD 4,577.70 million by 2032, reflecting a robust CAGR of 10%.

Recombinant Cell Culture Supplements Market

The global recombinant cell culture supplements market has witnessed steady growth in recent years and is expected to continue growing at a CAGR of 9.50% between 2023 and 2030.

Recombinant Plasma Protein Therapeutics Market

The recombinant plasma protein therapeutics market is set to grow from US$ 7,788.9 Mn in 2017 to US$ 15,910.5 Mn

Peptide Building Block Market

The Peptide Building Block Market is projected to grow from USD 2,525 million in 2024 to USD 4,436 million by 2032, registering a CAGR of 7.3% during the forecast period.

Hemophilia Treatment Market

The Global Hemophilia Treatment Market is projected to grow from USD 28,437.5 million in 2024 to an estimated USD 87,015.4 million by 2032, with a compound annual growth rate (CAGR) of 15.03% from 2025 to 2032.

Biosimilars Treatment Market

The Biosimilars Treatment market was valued at USD 18,067.2 million in 2018 and USD 28,308.5 million in 2024, and is anticipated to reach USD 51,025.8 million by 2032, at a CAGR of 7.66% during the forecast period.

Plasma Feed Market

The plasma feed market is projected to grow from USD 908.3 million in 2024 to USD 1,918.9 million by 2032, registering a CAGR of 9.8% during the forecast period.

Biofertilizers Market

The Biofertilizers Market size was valued at USD 2674.5 million in 2024 and is anticipated to reach USD 5136.7 million by 2032, at a CAGR of 8.5% during the forecast period.

Synthetic and Bio Thermosets Market

The Synthetic and Bio thermosets Market size was valued at USD 11,195 million in 2024 and is anticipated to reach USD 15,678.2 million by 2032, growing at a CAGR of 4.3% during the forecast period.

Isothermal Nucleic Acid Amplification Technology Market

The Isothermal nucleic acid amplification technology market is projected to grow from USD 623 million in 2024 to an estimated USD 1,259.7 million by 2032, with a compound annual growth rate (CAGR) of 9.2% from 2024 to 2032.

MEA Biologics and Biosimilars Market

The Middle East and Africa (MEA) Biologics and Biosimilars market size was valued at USD 457.69 million in 2018, increased to USD 649.05 million in 2024, and is anticipated to reach USD 1,023.42 million by 2032, at a CAGR of 5.45% during the forecast period.

Neuro Organoids Market

The Neuro Organoids market size was valued at USD 39.70 million in 2018, increased to USD 85.51 million in 2024, and is anticipated to reach USD 420.35 million by 2032, at a CAGR of 20.54% during the forecast period.

Lignin-Based Plastics Market

The Lignin-Based Plastics Market size was valued at USD 1,150.00 million in 2018 to USD 1,353.50 million in 2024 and is anticipated to reach USD 1,983.51 million by 2032, at a CAGR of 4.92% during the forecast period.

Olfactory Sensing ASIC Market

The Global Olfactory Sensing ASIC Market size was valued at USD 188.10 million in 2018 to USD 383.67 million in 2024 and is anticipated to reach USD 1,202.61 million by 2032, at a CAGR of 14.31% during the forecast period.

Bio-Integrated Sensor ASIC Market

The Global Bio-Integrated Sensor ASIC Market size was valued at USD 15,054.14 million in 2018 and is projected to reach USD 27,514.86 million by 2024. It is anticipated to grow to USD 66,163.22 million by 2032, at a CAGR of 10.80% during the forecast period.

Ocular Drug Delivery Technologies Market

The Ocular Drug Delivery Technologies market size was valued at USD 10,506.93 million in 2018, increased to USD 15,121.67 million in 2024, and is anticipated to reach USD 25,989.57 million by 2032, growing at a CAGR of 7.07% during the forecast period.

Molecular Weight Markers Market

The Molecular Weight Markers market size was valued at USD 387.3 million in 2018, grew to USD 841.4 million in 2024, and is anticipated to reach USD 2,259.8 million by 2032, at a CAGR of 13.19% during the forecast period.

Virus Safety Testing Services Market

The Virus Safety Testing Services Market size was valued at USD 657.4 million in 2024 and is anticipated to reach USD 2261.4 million by 2032, at a CAGR of 16.7 % during the forecast period (2024-2032).

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$12699

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Report delivery within 24 to 48 hours

What people say?

Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.

Materials Scientist
(privacy requested)

The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.

Imre Hof
Management Assistant, Bekaert